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Abstract 
Altered glycosylation is a universal feature of cancer cells, and certain glycans are well-known markers 
of tumor progression. Glycans are involved in fundamental molecular and cell biology processes 
occurring in cancer, such as tumor cell dissociation and invasion, cell–matrix interactions, immune 
modulation, tumor angiogenesis, and metastasis formation. 
Fucosylation, which comprises the transfer of a fucose residue to oligosaccharides and proteins, is 
regulated by many types of molecules, including fucosyltransferases. Fucosylation levels in normal 
colon is relatively low but increases during carcinogenesis.  
In the present work, we developed a molecular tool, through an adenoviral expression system to express 
the fucosyltransferase FUT8.  FUT8 enzyme is responsible for core alpha-(1,6)-fucosylation, which is 
reported to be increased in cancer, but its role in colorectal cancer (CRC) is still unknown. The FUT8-
adenoviral system reported here was used to transduce CRC cell lines, and the resultant transduced cell 
lines were evaluated for the FUT8 expression, for alpha-(1,6)-fucosylation and tested for implications 
on the hallmarks of cancer: proliferation, invasion and metastasis.  
Our data show that the overexpression of FUT8 increases the proliferation rate and increases the 
migration capacity of CRC cells. We also show that increased expression of FUT8 leads to changes of 
the expression of growth factors like TGF-β.  
Our results suggest that increased FUT8 expression in CRC is associated with increased malignancy 
and further studies should be envisaged to understand the underlying mechanisms.  
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Resumo 
A glicosilação aberrante é uma característica universal das células cancerígenas, sendo certos glicanos 
marcadores bem conhecidos da progressão tumoral. Os glicanos estão envolvidos em processos 
fundamentais da biologia celular e molecular que ocorrem no cancro, como a dissociação e invasão de 
células tumorais, interações célula-matriz, modulação imunológica, angiogénese tumoral e formação de 
metástases. 
A fucosilação, que compreende a transferência de um resíduo de fucose para oligossacáridos e proteínas, 
é regulada por vários tipos de moléculas, incluindo as fucosiltransferases. Os níveis de fucosilação nas 
células de cólon são relativamente baixos, mas aumentam durante a carcinogénese. 
No presente trabalho, desenvolvemos uma ferramenta molecular, através de um sistema de expressão 
adenoviral para expressar a fucosiltransferase FUT8. A enzima FUT8 é responsável pela alfa-(1,6)-
fucosilação nuclear, que é relatada como estando aumentada no cancro, sendo o seu papel no cancro 
colorretal (CRC) ainda desconhecido. O sistema FUT8-adenoviral descrito neste trabalho foi utilizado 
para transduzir linhas celulares de CRC, e as resultantes linhas celulares transduzidas foram avaliadas 
quanto à expressão de FUT8, quanto à alfa-(1,6)-fucosilação e testadas quanto a implicações nas 
características cancerígenas : proliferação, invasão e metastisação. 
Os nossos resultados mostram que a sobreexpressão de FUT8 aumenta a taxa de proliferação e aumenta 
a capacidade de migração nas células CRC. Também mostra que o aumento da expressão de FUT8 altera 
a expressão de fatores de crescimento como TGF-β. 
Os nossos resultados sugerem que o aumento da expressão de FUT8 no CRC está associado ao aumento 
da malignidade, no entanto outros estudos devem ser considerados para entender os mecanismos 
subjacentes. 
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1. Introduction 
1.1. Cancer  
In the last decade cancer caused 20% of deaths in Europe. It is one of the most important causes of death 
and morbidity in Europe after cardiovascular diseases and each year it is responsible for 1.7 million 
deaths and 3 million of new cases1. 
Cancer is the uncontrolled division of cells derived from genetic changes in a single cell or set of cells2. 
The changes can be triggered by inherent genetic factors and/or external agents like alcohol3, radiation3 
or tobacco3, and can affect almost any organ of the body. 
A cancer cell often invades surrounding tissue and can metastasize to distant sites.  
 
1.1.1. Hallmarks of cancer  
Cancer hallmarks can be defined as acquired evolutionary-advantageous characteristics that 
complementarily promote transformation of phenotypically normal cells into malignant ones. In cancer 
it is promoted the progression of malignant cells while sacrificing/exploiting host tissue4. 
Cancer hallmarks was a way fomented by scientists to organize principle for rationalizing the 
complexities of neoplastic disease and summarize the most common characteristics that malignant cells 
acquired to sustain their development.  
Initially, six hallmarks were defined by Hanahan and Weinberg: sustain proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis5.  One decade after the same researches did an updating of the 
hallmarks and added more two: the reprogramming of energy metabolism and evading immune 
destruction6.  
Nowadays the hallmarks of cancer can be summarized in a more organized and clearly way being 
individualized by Fouad and Aanei as: selective growth and proliferative advantage, altered stress 
response favoring overall survival, vascularization, invasion and metastasis, metabolic rewiring, an 
abetting microenvironment, and immune modulation4 (figure 1).  
Indeed, the most fundamental characteristic of cancer cells is their capability to sustain chronic 
proliferation and evading growth suppressors.  They acquired this ability using different ways of 
signaling: autocrine, paracrine and endocrine. 
 In the autocrine signaling, the tumor cells produce their own growth factor ligands and in response they 
overexpress the cognate receptors. In a paracrine signaling they produce growth factors and they release 
them to the adjacent target cells. Finally in an endocrine signaling the cancer cells can release the growth 
factors to the blood vessels in order to achieve distant cells6.  
Others strategies that cancer cells have to sustain a chronic proliferation could be downstream alterations 
of intracellular circuits resulting in constitutive receptor activation and recruitment of normal cells 
within the supporting tumor-associated stroma, to release growth factors to them6.  
Towards an uncontrolled proliferation, DNA damage, hypoxia and nutrient scarcity, the ability of the 
cancer cells to modify the stress response is considered another hallmark.  
Cancer cells can resist to apoptosis, either by the overexpression of anti-apoptotic proteins, namely by 
the loss of function of an important protein like the p53 protein4.  
Cancer cells also can escape from other mechanisms of defense against stress, as DNA repair and 
senescence. The senescence mechanism is a process that stops the cell cycle in an irreversible way7. A 
successive shortening of the telomeres in consequence of consecutive divisions induces the senescence 
to prevent a genomic instability and accumulation of mutations7,8. To overcome this obstacle the cancer 
cells upregulate the telomerase enzyme, that it is responsible for the reconstruction of the telomeres and 
allow a further replication8.  
Tumors need sustenance in the form of nutrients and oxygen as well a way to evacuate metabolic wastes 
and carbon dioxide. The tumor-associated neovasculature, created by the process of vascularization 
supply these necessities and allows a growth above 2-3 mm3 and the ability to form metastasis that 
would not be possible without new vasculature8.  
The major feature of malignancy involves the aptitude to invade surrounding and distant tissues to form 
secondary growths (metastasis). Cancer cells usually develop alterations in their shape as well as in their 
adhesion to other cells and to extracellular matrix (ECM). These alterations are result of a 
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downregulation of important molecules in cell-cell adhesion, e.g. e-cadherin and degradation of the 
ECM for metalloproteinases and cysteine cathepsin proteases9. 
In the multistage process of development and progression of a neoplastic disease there is not only 
alterations on the control of the proliferation but there are also adjustments of energetic metabolism.  
Normal cells under aerobic conditions process glucose into pyruvate via glycolysis in the cytosol and 
thereafter to carbon dioxide in the mitochondria. 
On other hand, tumor cells even under aerobic conditions, limited their energy metabolism and process 
glucose into lactate. The reprogrammed metabolism, limiting energy metabolism largely to glycolysis, 
facilitates the biosynthesis of the macromolecules and organelles required for assembling new cells by 
the diversion of glycolytic intermediates into various biosynthetic pathways4.  
To understand all the mechanisms involved in the oncogenesis process it is crucial to study the individual 
specialized cell types within the tumor as well as the “tumor environment” that surround them during 
the course of the process. Cancer cells and stromal cells have a continuous paracrine communication 
that creates a rich and dynamic microenvironment during all the stages of carcinogenesis6.  
The immune system can have a great influence during the oncogenesis process by its interaction with 
tumor cells. Under normal conditions, the immune system can activate the “cancer immunoediting”, 
process by which the immune system eliminates and shapes malignant cells. However, during the 
development of cancer, tumor cells gain the capability to evade the immune system and multiple cellular 
and molecular mechanisms by which tumor cells can escape the immune system have been identified.  
In this way, it becomes extremely challenging in the face of so many variables, to achieve the goal of 
fully elucidating the all mechanisms of cancer pathogenesis and to develop novel therapies able to 
successfully target both primary and metastatic tumors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- Hallmarks of cancer revisited. Currently, Fouad and Aanei defined 7 hallmarks: selective growth and 
proliferative advantage, altered stress response favoring overall survival, vascularization, invasion and metastasis, 
metabolic rewiring, an abetting microenvironment, and immune modulation. Fouad and Aanei,2017. 
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1.1.2. Colorectal cancer (CRC)  
Colorectal cancer (CRC) is a cancer that begins in the colon or in the rectum. Generally, colon and rectal 
cancer (depending on where they start) can be grouped because of many features that they share10.  
Both are cancers of the large intestine, which is the final part of the digestive tract. Most of the cases 
begin as small, noncancerous clumps of cells called adenomatous polyps.  
Polyps are small and produce few, if any, symptoms, making very difficult an early diagnosis. 
 For this reason, it is recommended regular screening tests to prevent colorectal cancer by the 
identification and removal of polyps before they became CRC.   
In most cases, the causes of the disease are not clear, but some studies showed an association between 
diet and cancer. In diets riches in fat and with a low content of fibers were verified an increase of the 
risk of these cancers11.  
Other factors that may increase the risk of CRC include an older age, inflammatory intestinal conditions, 
inherited syndromes that increase colon cancer risk, like hereditary nonpolyposis colorectal cancer, a 
sedentary lifestyle, diabetes, smoking and alcohol12.  
In 2012, the estimated incidence rates in males varied from <5 (per 100 000) in several African countries 
to over 40 in certain countries in Europe, Northern America and Oceania (figure 2)13. 
So, it is crucial to find new methods of diagnosis for a disease that in most of the cases, as was mentioned 
before, do not present symptoms and it is one of the most common causes of cancer-related death in 
women and men14.  
  
 
 
 
Figure 2- Worldwide colorectal cancer incidence and mortality rates.  (Age adjusted according to the world standard 
population, per 100 000) in males in 2012 (GLOBOCAN 2012). The estimated incidence rates in males varied from <5 (per 
100 000) in several African countries to over 40 in certain countries in Europe, Northern America and Oceania. Adapted 
from Sierra, 2017. 
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1.2. Carbohydrates- The sweet side of the life  
Carbohydrates are the most abundant among the major classes of biomolecules belonging to a class of 
organic compounds found in living organisms on earth.  
They can be represented by the stoichiometric formula (CH2O)n, where n is the number of carbons in 
the molecule. This formula also explains the origin of the term carbohydrate, that means “hydrates of 
carbon”15. 
Monosaccharides (mono– = “one”; sacchar– = “sweet”) are simple sugars in which the number of 
carbons usually ranges from three to seven. The sugars can be classified as aldose or ketose, depending 
if the functional group is an aldehyde or a ketone, respectively. The monosaccharides also can be known 
as trioses (three carbons), pentoses (five carbons), and or hexoses (six carbons), according with the 
number of carbons.   
Disaccharides (di– = “two”) are composed by two monosaccharides units and oligosaccharides (oligo- 
= few) are composed by 3 to 10 monosaccharides.  
A long chain of monosaccharides linked by glyosidic bonds is known as a polysaccharide (poly– = 
“many”). The chain may be branched or unbranched, and it may contain different types of 
monosaccharides16.  
Glycosylation is most abundant protein post-translational modification, which is essential for many 
biological processes. It is a complex process including numerous functional proteins and resulting in a 
great diversity of carbohydrate–protein bonds and glycan structures. 
Glycosylation of some proteins has a great impact on their structures and functions, and interactions of 
protein‐linked glycans with carbohydrate‐specific proteins (lectins) modulate many important biological 
processes17. 
 
1.3. Glycosylation 
Glycosylation is one of the most common post-translational modifications mediated by the enzymatic 
addition of glycans to proteins or lipids.  Transmembrane receptors, organelle-resident proteins, secreted 
proteins and surface proteins, as well as many others are modified by glycosylation to regulate their 
structure, stability and function. 
The glycans can be found in a free form or linked by covalent bonds to proteins (glycoproteins and 
proteoglycans) or lipids (glycolipids), identified as glycoconjugates (figure 3).  The glycoconjugates can 
be classified by the identity of the carrier molecule and by the type of the glycosidic linkage17.  
The biosynthesis of glycoproteins occurs in in the lumen of the Endoplasmic Reticulum (ER) and/or 
Golgi Apparatus, but also in the Cytoplasm and Plasma Membrane. Proteins can be N-glycosylated, O-
glycosylated, and modified with glycosylphosphatidylinositol (GPI) anchors, and some called 
proteoglycans are modified with glycosaminoglycan chains. 
 
N-glycans, in which the glycans are attached to the amine group of an asparagine (Asn) residue of a 
protein side chain, especially to the motif Asn-X-Ser/Thr18. 
O-glycans in which glycans are attached to serine (Ser) or threonine (Thr) residues on glycoproteins, 
mainly on secreted and membrane bound mucins; and glycosaminoglycans (or proteoglycans) in which 
the glycan structure is also attached to Ser or Thr but differs from O-glycans by consisting of linear 
molecules which are often sulfated19. The glycolipids are the result of the lipid glycosylation and can be 
represented by glycoglycerolipids and glycosphingolipids. The main role of the glycolipids is to 
maintain the stability of the cell membrane and to facilitate cellular recognition, which is crucial to the 
immune response20. 
Other subclasses of glycoconjugates include glycosylphosphatidylinositol (GPI)-linked proteins, which 
are proteins that bear a glycan linked to phosphatidylinositol. 
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1.3.1. N-glycosylation 
Glycosylation is considered to be one of the most prevalent mechanisms of protein post-translational 
modifications. It is proposed that more than half of all eukaryotic proteins are glycoproteins and 90% of 
these proteins carry N-linked glycans21.  
N-glycosylation takes place in the ER and in Golgi apparatus22. The first stage of the N-glycosylation 
biosynthetic pathway in mammalian cells involves the assembly of a 14-oligosaccharide “core” unit as 
a membrane bound dolichyl pyrophosphate (Dol-P-P) lipid precursor by enzymes located on both sides 
of the ER membrane22,23.   
This core oligosaccharide is common to most eukaryotes and has a defined structure containing three 
glucoses (Glc), nine mannoses (Man) and two GlcNAc residues24.  
After the biosynthesis of core oligosaccharide, it is transferred to the nascent protein by the 
oligosaccharyltransferase, a complex enzyme with its active site in the ER lumen, via a N-glycosidic 
linkage of a GlcNac to an Asn residue (figure 4). The Asn residue must be part of the consensus amino 
acid sequence Asn-X-Ser/Thr, where X can be any amino acid, except proline25. Before exiting the ER, 
Figure 3- Representative image of different types of glycoconjugates.  N-glycans are covalently attached to proteins at 
asparagine (Asn) residues by an N-glycosidic bond. The enzyme N-acetylglucosaninyltransferase V (GnTV) generates a 
specific antenna on some glycoproteins and has been implicated in tumour invasion. O-Linked glycans are covalently attached 
to the peptide chain through serine or threonine residues on glycoproteins and mucins. SLeX/A (sialyl Lewis X or A) are 
glycans determinants composed of four sugars in specific linkage to one another and are frequently overexpressed on tumor-
cell mucins. Tn and STn are tumor antigens that contain truncated O linked chains and their accumulation in several cancers 
is associated with invasion. Proteoglycans participate in growth factor activation and cell adhesion. Adapted from Fuster, 
2005.  
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takes place a removal process of the two outermost Glc residues and mannose residues by the activities 
of α-glucosidases (I and II) and mannosidases. When the glycoprotein moves to the Golgi complex, the 
glycan chains undergo further trimming of mannoses before further extension of the glycan branches.  
Following step-wise adding of sugars to different positions of the extending glycan is catalyzed by many 
glycosyltransferases, each adds a specific monosaccharide through a glycosidic bond.  
 
1.3.2. O-glycosylation 
The O-linked glycosylation takes place in the Golgi apparatus and consist on the sequentially addition 
of monosaccharaides residues or glycan structures to Ser or Thr residues of the protein backbone (figure 
4). There is no consensus sequence and there are multiple types of O-linked glycans (e.g. O-GalNAc, 
O-GlcNAc, O-α-Fuc, O-β-Glc, O-β-Gal)26. The main forms of O-glycans on higher eukaryotic secretory 
proteins are mucin-type glycans27. The synthesis of the mucins begins with the addition of an GalNAc 
residue to a Ser/Thr side chain, followed by the construction of one of the four distinct core structures 
by the addition of Galactose (Gal) and GlcNAc residues in many linkages27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.3. Glycan’s biological function 
Glycosylation creates a huge repertoire of glycan structures whose variety derives from the cell-specific 
expression levels and intracellular location of the enzymes involved and the availability of sugar 
substrates.  
Glycans play different roles according to the molecule to which it is attached, the development stage 
and the biological context and its location. They are involved in many different biological functions and 
their significance varied cellular interactions depends on their extracellular location.  
The functions of glycans comprise the specific recognition by other molecules- most commonly, glycan-
binding proteins; the regulation of protein stability, solubility and vulnerability to enzymatic 
degradation; intracellular and intercellular communication; regulation of receptor activation and signal 
transduction28. They also present structural and modulatory properties29.  
Figure 4- N-glycans and O-glycans sctructure. N-glycans are linked via a N-linkage to Asn and their synthesis begins on a 
lipid-like polyisoprenoid molecule termed dolichol-phosphate (Dol-P) in eukaryotes. Following synthesis of an 
oligosaccharide that contains as many as 14 sugars, the N-glycan is transferred “en bloc” to protein. O-glycans are linked via 
an O-linkage to Ser/Thr. The synthesis of O-glyacans begins with the addition of the monosaccharide GalNAc (from UDP-
GalNAc) to serine and threonine residues catalyzed by a polypeptide GalNAc transferase (GalNAcT) and in contrast to N-
glycosylation, a consensus sequence for GalNAc addition to polypeptides has not been found Adapted from Pinho and 
Reis,2015. 
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Given such important functions, alterations on the structure of the oligosaccharides leads to changes in 
aspects like proliferation, differentiation, migration, tumor invasion, cell-trafficking and trans-
membrane signaling30.  
 
1.3.4. Hallmarks of glycosylation in cancer  
It is well known that fundamental changes in the glycosylation pattern of cell surface occur during 
malignant transformation and cancer development. The significance of glycosylation in cancer is further 
highlighted by the fact of most of the Food and Drugs Administration (FDA)- approved tumor markers 
are glycoproteins or glycan antigens30,31.  
Glycosylation is itself a hallmark of cancer and recent studies have shown that glycans play a role in 
many hallmarks of cancer (figure 5).  
The principal characteristic of cancer is their ability to maintain chronic proliferation. It was verified 
that the expression of N-glycans and their branching degree can control the activity and signaling of 
different growth factor receptors and has a significant role in the proliferative signaling32. Many growth 
factor receptors, including TGF-beta, EGFR, FGFR, PDGF, MET and IGFR33 are known to be regulated 
by glycosylation. 
Invasion and metastasis are features of a lot of tumors and evidences propose that certain glycans are 
involved in these processes. E-cadherin, a transmembrane glycoprotein, which connects epithelial cells 
together at adherent junctions plays an essential role in the suppression of cancer cell migration and 
metastasis. This protein has four potential N-glycosylation sites and many studies have hypothesized 
that different expression profiles of E-cadherin-linked N-glycans may be related to the stability of 
adherent junctions. Thus, modifications by N-glycosylation have been proposed to underlie E-cadherin 
downregulation or inactivation in cancer34. 
Apoptosis represents energy-requiring, spontaneous single cell death, with specific morphological and 
biochemical features, and the capability of cancer cells to evade that process is considered another 
hallmark of cancer.  The glycosylation of death receptors and their ligands may critically control 
apoptosis by disrupting ligand-receptor interactions, influencing ligand secretion from effector cells and 
modulating the formation of signaling complexes35.  
Cancer cells have a higher need of nutrients and oxygen as well as a way to remove metabolic waste 
like e.g. carbon dioxide. Different glycosylation associated genes has been linked to the angiogenesis 
process by the vascular endothelial growth factor receptor-2 (VEGFR-2), that is an important receptor 
tyrosine kinase (RTK)36. 
The extracellular domain of VEGFR-2 is composed of seven immunoglobulin-like domains, each with 
multiple potential N-glycosylation sites. N-glycosylation plays a central role in RTK ligand binding, 
trafficking, and stability and altered glycosylation may affect its function36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5- Hallmarks of Glycosylation in cancer. Glycosylation is a characteristic that is associated with the acquisition and 
development of cancers. Recent studies have shown that glycans play a role in every recognized cancer hallmark (sustaining 
proliferative signaling, evading growth suppressors, deregulating cellular energetics, resisting cell death, enabling replicative 
immortality, activation invasion and metastasis, inducing angiogenesis, genome instability and mutation, tumor promoting 
inflammation and avoiding immune destruction). 
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1.3.5. Glycosylation characteristics of colorectal cancer 
As was mentioned before, an aberrant glycosylation has many functional consequences, contributing to 
the progression, severity and dissemination of CRC. 
Glycans have been found to contribute in many fundamental biological processes involved in cancer, 
such as tumorigenesis and metastasis.  
Tumorigenesis is a multistep process, the progression of which depends on a sequential accumulation 
of mutations within tissue cells. The glycosylation plays an important role of the multiple cell survival 
pathways and consequently in tumorigenesis.  
It was found an overexpression of N-acetylglucosaminyltransferase, GnT-V, in CRC cells37. The 
increase of the expression of this glycosyltransferase plays a crucial role in the regulation of these 
oncogenic processes.  
 GnT-V is an enzyme that catalyzes beta 1-6 branching of N-acetylglucosamine on N-linked 
oligosaccharides. Its product, the beta 1–6 branching structure, is further elongated  forming poly- N-
acetyllactosamine and the level of this residue is increased in highly metastatic colon cancer cells38.  
The increase of  polylactosaminylation on N-glycans of surface receptors such as growth-, arrest-, and 
angiogenesis promoting receptors, may has an effect in the tumor invasion and angiogenesis, because 
the galectin 3 with these modified residues induces the formation of molecular lattices, which delay the 
endocytosis of them and maintain their responsiveness to the ligand39.  
The O-glycosylation also plays an important role in the regulation of CRC cell growth40. 
The tumor infiltrating cells express the sialic acid-binding immunoglobulin-like lectin 9 (singlec-9) and 
its interaction with sialylated O-glycans of the cancer-associated transmembrane mucin protein MUC1 
on CRC cells was shown to induce the recruitment of β-catenin and to promote tumor growth40,41.  
GnT-V also plays an important role in the formation of metastasis. The increase of its product is 
associated with cancer invasion and metastasis in CRC cause the GnT-V-mediated glycosylation 
changes on, e.g. matriptase, β1-integrin, and N-cadherin, proteins involved in cell adhesion, regulate 
tumor cell motility by decreasing cell-cell adhesion and increasing the interaction between cells37.  
 
1.4. Fucosylation  
Fucose (6-deoxy-L-galactose) is a monosaccharide that is found in glycoproteins and glycolipids present 
in vertebrates, invertebrates, plants, and bacteria. 
The attachment of fucose residues to oligosaccharides and proteins by the activity of innumerous 
glycosyltransferases comprises one of the most common modifications of glycans on proteins or lipids. 
This process is regulated by different types of molecules, as glycosyltransferases, in particularly 
fucosyltransferases, guanosine diphosphate (GDP)-fucose synthetic enzymes, and GDP-fucose 
transporters.  
The proteins that catalyzed this reaction, fucosyltrasnferases, can be classified based on the sites of 
fucose addition into α1,2-(FUT1 and FUT2), α1,3/4-(FUT3 to 7 and FUT9 to 11), α1,6-(FUT8), and O-
(POFUT1 and POFUT2) FUTs42.  
In the present work we will focus on fucosyltransferase 8 (FUT8). This enzyme is the only 
fucosyltransferase involved in core fucosylation (addition of fucose in α-1,6-linkage to the innermost 
N-acetyl glucosamine of N-glycans). Core fucosylation of glycoproteins has significant regulatory 
functions for adhesion molecules and growth factor receptors, such as α3β1 integrin and epidermal 
growth factor receptors43. 
 
1.4.1. FUT8 
1.4.1.1. FUT8 structure and localization in cells  
The gene encoding fucosyltransferase 8 protein is located on chromosome 14q23.3 and encompasses 
approximately 333 kb.  Its sequence contains nine exons with coding regions and three 5'-untranslated 
exons43.  
FUT8 was first purified and cloned from the porcine brain and from a human gastric cancer line and it 
consists of 575 amino acids and it has a molecular weight of 66516 Da43. The protein contains no N-
glycosylation sites and belongs to the GT23 family of the CAZy classification44. 
The global structure of FUT8 consists of three domains: a catalytic domain, an N-terminal coiled-coil 
domain, and a C-terminal SH3 domain. 
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The enzyme catalyzes the transference of a fucose residue from GDP-fucose to the reducing terminal 
GlcNAc of Asn-linked oligosaccharide (N-glycan) via an α1,6-linkage and the resultant fucosyl residue 
is referred to as a core fucose (figure 6). The donor substrate and the acceptor substrate for FUT8 are 
GDP-fucose and a biantennary N-glycan, respectively. The GDP-fucose is synthesized in the cytoplasm 
through both de novo pathway and the salvage pathway. In de novo pathways, the GDP-mannose is 
transformed to GDP-fucose, via three enzymatic reactions carried out by GDP-mannose 4,6-
deoxymannose (GMD) and GDP-keo-6-deoxymannose 3,5-epimerase, 4-reductase. The savage 
pathway synthesizes GDP-fucose from free L-fucose derived from extracellular or lysosomal sources45. 
FUT8 was detected on cytosol and Golgi Aparatus46 and its physiological significance has been 
confirmed by genetic ablation of the fut8 gene: 80% of these mice die three days after birth and the 
survivors present severe growth retardation47. 
 
 
 
 
 
 
 
 
 
 
1.4.1.2. FUT8’s implications in cancer  
Over the time various studies were conducted to study and understand the significance and impact of 
FUT8 on cell growth and differentiation, since was reported that the enzyme is widely expressed in 
mammalian tissues and there is an increase in its expression in different cancerous tissues.  
FUT8 mRNA expression and activity are highly elevated in cases of ovarian serous adenocarcinoma, in 
comparison with normal ovary. The elevated expression of FUT8 and the subsequent modifications of 
N‐glycans constitute a significant characteristic of this kind of ovarian cancer48. 
In thyroid cancer was found that 33,3% of the cases of papillary carcinoma present an overexpression 
of FUT8 and the enhancement of the expression of this fucosyltransferase was associated with tumor 
size and lymph node metastasis49.  
It is known and well study that the alpha-fetoprotein (AFP), the major fetal plasma protein, plays an 
important role in the development of hepatocellular carcinoma (HCC)50.  
A core-fucosylated isoform of AFP, AFP-L3, was identified and was found that the expression of this 
protein it is highly in HCC tissue51.  
The expression of FUT8 is high in HCC tissue and in liver cirrhosis, but surprisingly, was not observed 
a concomitant elevated expression of AFP-L3 in liver cirrhosis. This inconsistency can be explained by 
the difference in the synthesis of GDP-fucose, the donor substrate for fucosyltransferases, as FUT8, 
because the expression of GDP-fucose is higher in HCC, as compared to a liver cirrhosis. Thus, it 
appears that AFP-L3 could be used as a marker for HCC51. 
Another evidence that shows that FUT8 play an important role in cancer is the elevate expression of the 
haptoglobin, a highly fucosylated glycoprotein in serum of patients with pancreatic cancer.  
Structural analyses using mass spectrometry and lectin blotting showed that core fucosylation is 
increased in haptoglobin from serum of these patients. Thus, Fucosylated haptoglobin could be a novel 
marker for pancreatic cancer52. 
 
Figure 6- Catalytic reaction of FUT8. FUT8 catalyzes the transfer of a fucose residue to the innermost GlcNAc from GDP-
fucose. The reaction does not require any divalent cations or cofactors and the resultant fucosyl residue is referred to as a core 
fucose. From Naoyuki Taniguchi and Yasuhiko Kizuka, 2014. 
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1.4.1.2.1. FUT8 and CRC 
A specific increase in FUT8 expression and its enzyme activity have been reported in innumerous human 
tumor processes such as ovarian serous adenocarcinoma, thyroid cancer, HCC and pancreatic cancer, as 
mention before.  
In CRC the behavior and significance of FUT8 remain almost unknown, but some studies have shown 
that FUT8 activity is considerably elevated in some colorectal tumors as compared with the surrounding 
healthy tissues53. 
The activity of FUT8 and standard clinicopathological features exhibited significant correlations 
between the protein activity and lymph node infiltration, tumor stage and type of growth54.  
Studies revealed an increase in the FUT8 activity in polypoid tumors, more localized and less invasive 
than non-polypoid tumors and corresponded to the increase observed in tumors without lymph node 
metastasis. Likewise, was detected a progressive decrease in FUT8 activity as the degree of infiltration 
in the intestinal wall progressed54.  
Therefore, considering these evidences, was postulated a hypothesis that the increase in the enzyme 
activity, in combination with different cell alterations produced during the malignant process, would be 
involved in the initial development of the tumors, since the initial steps of this development are 
characterized by the uncontrolled division of the transformed cells54.  
In other hand, the decrease of the FUT8 activity in advanced stages could the linked to the acquisition 
of the invasive potential of the tumor cells. 
 
1.4.1.3. FUT8 in anti-cancer therapy 
The antibodies have multiple therapeutic functions like e.g. antigen biding, induction of apoptosis, 
complement-dependent cellular cytotoxicity but the antibody-dependent cellular cytotoxity (ADCC) is 
considered one of the most important function of some antibodies used for therapy.  
ADCC is the mechanism that comprehends the killing of an antibody‐coated target cell by a cytotoxic 
effector cell through a nonphagocytic process, characterized by the release of the content of cytotoxic 
granules or by the expression of cell death‐inducing molecules.  This mechanism is triggered upon 
biding of lymphocytes receptors (FcγRs) to the constant region (Fc) of the antibodies55 (figure 7). 
So, it is crucial to find ways to improve and enhance the mechanism of the antibody-dependent cellular 
cytotoxicity. Recent studies have shown that engineering the oligosaccharides of IgGs may yield 
optimized ADCC. Analysis of different studies showed that recombinant IgG1 produced by rat 
hybridoma YB2/0 cells presents at least 50-fold higher ADCC that that produced by CHO cells, one of 
the most used host cell lines for production of recombinant antibodies56.  
YB2/0 cells expressed a lower level of FUT8 mRNA than CHO cells, and overexpression of FUT8 in 
YB2/0 led the increase of fucosylation of IgG1 and decrease of ADCC56.  
In the study conducted by Shields, they demonstrated that nonfucosylated anti-Her2 humanized IgG1 
and anti-IgE humanized IgG1 produced by a variant of CHO cells, Lec13, had enhanced ADCC relative 
to fucosylated IgG1s produced by normal CHO cells57.  
These results suggest that Fuc-deficient IgG1 may need a lower concentration of antibody on the surface 
of the target cell to activate an effector cell and start the ADCC mechanism. There are a few possible 
explanations of why the antibodies with nonfucosylated oligosaccharides give rise to stronger binding 
to FcγRIIIa than those in which the glycoforms are absent56. A core Fuc has been shown to influence 
the conformational flexibility of biantennary oligosaccharides56.  
These reports have suggested that therapeutic antibodies with improved ADCC including the 
nonfucosylated IgG1 would result in the improvement of clinical response and reduce the cost of the 
antibody therapy, since these findings may allow for use of the nonfucosylated IgG1 at lower doses with 
no reduction in efficacy.  
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Figure 7- Representative image of antibody-dependent cellular cytotoxicity. Antibody-dependent cellular cytotoxicity is 
an immune mechanism through which Fc receptor-bearing effector cells can recognize and kill antibody-coated target cells 
expressing tumor- or pathogen-derived antigens on their surface. Effector cell of the immune system actively lyses a target 
cell, whose membrane-surface antigens have been bound by specific antibodies, release cytokines and promote the death of 
the target cells.  
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2. Aims of this thesis work 
Bearing in mind, that an increase in FUT8 expression and activity has been associated with many human 
tumors such as ovarian serous adenocarcinoma, thyroid cancer, HCC, pancreatic cancer and CRC, it is 
vital to get supplementary understandings on the role of FUT8 in cancer.  
The FUT8 behavior and its implication in CRC remains almost unknown, but there are some reports 
linking the activity of the protein and standard clinicopathological features as tumor stage and type of 
growth. Thus, it is important to develop molecular tools enabling the control of FUT8 expression in 
order to try to reveal its implications in this particular type of cancer.  
According to this, the main goals of this project were the development of a molecular system with the 
objective to modify FUT8 expression; validate this system in HEK293A and HT29 cell lines and study 
the impact of FUT8 modulated expression in CRC cells phenotype as well in the expression of different 
growth factors. 
The first major step of this work was the construction of the FUT8-adenoviral system, in collaboration 
with Dr. José Ramalho, from CEDOC, FCM/UNL, using the Gateway Technology. In this first phase 
of the project several cloning techniques were used. 
After the expression system obtained, the final plasmid was transfected into the HEK293A cell line. 
This cell line was also chosen to produce the adenovirus particles and then to perform a mini-scale 
production of FUT8 with the aim of purifying the protein. 
The purification of the protein was carried out with the purpose of evaluating its activity in order to 
verify if the purified protein could be used in a partnership with the group led by Dr. Daniel Varon Silva, 
from Max Planck Institute, which works on glycoprotein synthesis. In this particular case, FUT8 would 
be used to catalyze the transfer of α1,6-linked fucose to the first N-acetylglucosamine in N-linked 
glycans. 
In a second phase of the project, this time working with the Glycoimmunology lab group, led by 
Professor Paula Videira, an evaluation was made regarding the implication of FUT8 in the CRC HT29 
cell line. Properties such as proliferation and migration, as well as the expression of growth factors of 
cells that underwent FUT8 expression modulation were evaluated. 
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3. Materials and Methods 
3.1. Adenoviral system- General introduction 
The Adenoviral Expression System (InvitrogenTM, Life Technologies, USA) is an adaptation of the 
Gateway® System 58 that allows the creation of a replication incompetent adenovirus that can be used 
for delivery and transiently express a gene of interest in dividing and non-dividing mammalian cells. 
Choosing an adenoviral vector as a destination can be achieved, high efficiency generation of 
recombinant adenovirus containing our gene of interest under the control of the human cytomegalovirus 
(CMV) promoter. 
The use of the Gateway® Technology bring advantages like a highly efficient, rapid cloning of the gene 
of interest and create efficiently delivers the gene to mammalian cells in culture.  
3.1.1. Adenovirus structure 
The adenovirus are non-enveloped virus with linear, double-stranded DNA genome of 26-45 kb. Its 
structure is comprised by a nucleocapsid in the form of 3 major types: fiber, peton and hexon based 
proteins. The basis of the adenovirus structure is conferred by the hexon and it composes most of the 
viral capsid. The peton based proteins and fiber are for receptor binding and internalization of the 
adenovirus into host cells 59. 
The adenoviral system basically comprehends the entry of the adenovirus to the cells by binding the 
Coxsackie and adenovirus receptor (CAR) 60. After the binding of the adenovirus, the internalization is 
conducted via integrin-mediated endocytosis and the transport to the nucleus it is achieved by active 
transport 61. By the time that the adenovirus reaches the nucleus the early phase starts take place the 
transcription and translation of the early genes, followed by the expression of the adenoviral late genes 
and viral replication (figure 8). The viral replication is dependent of the expression of the E1 protein 
and as the adenovirus used in the present study are replication incompetent particles the E1 is supplied 
by the HEK293A producer cells. 
  
Figure 8- Schematic representation of structure of adenovirus (A) and adenoviral replication (B). Adenovirus attaches 
to the host cell via its fiber structure to Coxsackie and Adenovirus receptor (CAR) receptor on host cell. The attachment of 
fiber to its receptor on host cell is followed by interaction of penton base with cellular integrin which promote receptor 
mediated internalization. The viral nucleocapsid is transported from cytosol to nucleus by the help of microtubules and it is 
there that the viral DNA replication takes place. 
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A. FUT8 overexpression-encoding plasmid 
One plasmid was constructed with the aim to produce adenovirus particles to overexpress FUT8. The 
pAd/CMV/V5-DEST was the plasmid that was chosen as a destination vector and contain the following 
elements: human adenovirus type 5 sequences encoding genes (Right Inverted Terminal Repeats (ITRs), 
encapsidation signal sequence, late genes) and the elements required for proper packaging and 
production of adenovirus. A Chloramphenicol resistance gene (CmR) located between the two attR sites 
for counterselection, two recombination sites, attR1 and attR2 for recombinational cloning of the DNA 
sequence of interest from an entry clone, and a human cytomegalovirus (CMV) immediate early 
promoter for high-level constitutive expression of the gene of interest in a wide range of mammalian 
cells. An Ampicillin resistance gene for selection in E. coli and pUC origin for high-copy replication 
and maintenance of the plasmid in E. coli (figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 9- Schematic representation of the Gateway reaction to create expression clone (A) and a schematic 
representation of the Adenoviral vector with our gene of interest. 
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3.2. Cloning techniques  
The first step of this work was the construction of the recombinant protein. The gene was synthesized 
by GeneCust company (Luxembourg) and we decided to add a Histidine tail (His tag) in the N-terminal 
position of the sequence in order to facilitate the purification process. 
We also decided to add a thrombin site between a His tag to simplify a possible separation of His tag 
from the protein coding sequence of interest (figure 10). 
 
After obtained the plasmid with the synthesized FUT8 encoding gene, different cloning techniques were 
used, first with the aim of obtaining the Gateway Technology pENTR vector and afterwards with the 
aim to get the final vector, the adenoviral plasmid which we will use to overexpress the 
fucosyltransferase 8. 
The plasmid was assembled using consecutive cloning strategies. Briefly, all the cloning was executed 
as follows: isolation and purification of the obtained plasmid DNA with the synthesized FUT8 encoding 
gene, enzymatic restriction digestion, Gateway reaction (BP reaction), transformation of competent cells 
with the resulting plasmid, PCR screening of the colonies, isolation and purification of the Gateway 
plasmid, confirmation of the construct by digestion with restriction enzymes, Gateway Technology 
reaction (LR reaction), transformation of competent cells with the resulting plasmids, PCR screening of 
the colonies, isolation and purification of the Gateway plasmid, confirmation of the construct by 
digestion with restriction enzymes and sequencing of the final plasmid.   
 
3.2.1. Plasmids isolation and purification from bacterial culture 
The plasmids were purified with mini and midi kits (Omega Bio-Tek, USA and Zymo Research, USA, 
respectively) and both rely on the same principle: centrifugation to obtain a pellet of the bacteria; 
resuspension and lyse to expose the genetic material and proteins, removal of RNA and protein, biding 
the DNA to a specific column, wash and elution of the DNA from the biding column. 
3.2.1.1. Miniprep 
The E.Z.N.A® Plasmid DNA Mini Kit I (Omega Bio-Tek, USA) was used to isolate and purify plasmid 
DNA in accordance with the manufacturer’s recommendations. Cells from 10ml bacterial culture were 
harvested and the plasmid DNA was eluted in 100 μL of Tris (pH 7,4). 
Figure 10- Schematic representation of the PCR product of the recombinant human protein. The recombinant protein 
has a histidine tail (His tag) in the N-terminal position of the sequence in order to facilitate the purification process. It also has 
a thrombin site between a His tag and the encoding sequence of FUT8 to make simpler a possible separation of them. 
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3.2.1.2. Midiprep 
Plasmid DNA isolation and purification from 50 mL cultures were done with the Zymo Pure Plasmid 
Midiprep Kit (Zymo Research, USA) according to the manual. 
3.2.2. Agarose gel electrophoresis 
DNA was separated according to size and evaluated on 0,8% agarose gel by electrophoresis. Before 
electrophoresis, appropriate volume of loading buffer was added to each sample. 
The size standard GeneRuler™ 1kb DNA ladder (Thermo Fisher Scientific, USA) was used to determine 
the size of the migrated DNA fragments. The gel was run in 1x TAE buffer (40mM Tris-acetate, 1mM 
EDTA) for 20-30 minutes.  
3.2.3. Enzymatic restriction digestion 
PCR products and the vectors were digested with restriction enzymes to prepare them for the Gateway 
reactions and to confirm the constructions through horizontal agarose gel electrophoresis. 
To digest the vectors and inserts were used NheI and PacI enzymes (Takara Bio, USA) and the digestions 
were performed at 37 ºC during 1 h, as described by the manufacturer.  
3.2.4. Cloning of DNA fragments using the Gateway Cloning Technology 
The Gateway® Technology is based on the bacteriophage lambda site-specific recombination system 
which allows the integration of lambda into E. coli chromosome and switch between the lytic and 
lysogenic pathways62. This technology has some modifications of the components of the lambda 
recombination system to improve the specificity and efficiency of the system63.  
The Gateway® Technology has to main reactions: 
- BP reaction:  This reaction is catalyzed by BP Clonase™ enzyme mix and enable the 
recombination of an attB substrate (attB-PCR product or a linearized attB expression clone) 
with attP substrate (donor vector) to generate an attL substrate (entry clone) (Figure 11). 
 
 
 
 
 
 
Figure 11- Schematic representation of BP reaction from the Gateway® Technology. The reaction comprehends the 
recombination of an attB- PCR product and a Donor vector (attP substrate) in order to create an Entry Vector containing the 
attL sites. 
- LR Reaction: Facilitates recombination of an attL- containing entry clone with an attR substrate 
(destination vector) to create an attB substrate (expression clone) (Figure 12). This reaction is 
catalyzed by LR Clonase™ enzyme mix. 
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3.2.4.1. BP reaction 
This reaction was performed by mixing the PCR product containing our gene of interest and flanked by 
the attB sequences with the pDONR vector, being catalyzed by the BP Clonase™ enzyme mix. 
The purpose of this reaction was to obtain an entry vector that would serve as a substrate for the LR 
reaction. 
 
3.2.5. Bacterial Strain 
Escherichia coli (E. coli) HB101 (Promega, USA) competent cells were used to produce the DNA 
plasmids. 
 HB101 is a hybrid K12 X B strain bacterium containing the recA13 mutation that minimizes 
recombination and aids in insert stability. Additionally, this strain carries the hsdS20(rB- mB-) 
restriction minus genotype which prevents cleavage of cloned DNA by endogenous restriction enzymes. 
The bacteria transformation was performed following the manufacturer's instructions and working banks 
of transformed bacteria for each used plasmid were created. The bacteria suspension was mixed with 
50% of glycerol, aliquoted and frozen at -80 ºC. 
Briefly, plasmid DNA was placed in contact with HB101 cells for 30 minutes on ice, after that the cells 
were incubated at 42ᵒC for 1 minute. Following the previous steps, the HB101 cells were incubated for 
3-4 minutes at 0ᵒC and afterwards, LB medium was added to the cells and incubate for 1,5 h at 37ᵒC 
while shaking with the require antibiotic in order to allow them to acquire the antibiotic resistance and 
to grow. 
After transformation, bacteria were spread on agar plates. The agar plates were prepared with Agar 
(NZYTech, Portugal) accordingly to the manufacturer’s instructions. 
Following the inoculation, bacteria were grown at 37ºC for 16- 17 hours. Single and well individualized 
colonies were picked from the previously inoculated agar plates and each colony was grown in a small 
volume LB medium (5 mL in 50 mL tubes) at 37 ºC for 16-17 h in an orbital shaker at 150 rpm. 
 
3.2.6. Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) was used to amplify desired segments of DNA. 
Following three steps, the target sequence is amplified. First, denaturation of the template occurs by 
heating, second, primers flanking the target sequence anneal to their complementary sequences, and 
during the last step the annealed primers are extended by DNA polymerase. The cycle is repeated and 
leads to an exponential amplification of the DNA segment (figure 10).  
We amplify our sequence and flanked them with gateway sequences (attB sites) to obtain expression 
clones. We selected the bacteria colony containing the vector of interest, a screening colony PCR was 
performed with GoTaq DNA Polymerase (Promega, USA) using specific primers for each construct 
enabling to infer the successful cloning. 
After the screening, one single positive colony was incubated and grown in LB medium supplemented 
with appropriated antibiotic for 24 h at 37ᵒC. 
Figure 12- Schematic representation of the LR reaction from Gateway® Technology. In this reaction the aim is to 
generate an Expression vector by the recombination of the Entry vector generated in the BP reaction with a Destination 
vector. 
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3.2.6.1. LR reaction 
The LR reaction took place between the attL sites of the generated entry clone that was obtained by the 
BP reaction and the attR sites of the destination vector. The reaction was catalyzed by the LR Clonase 
enzyme mix and as a result, an expression clone with the DNA of interest flanked by attB sites was 
generated. 
As a destination vector was choose an adenoviral vector, pAd/CMV/V5-DEST™, where our sequence 
of interest was controlled by the human cytomegalovirus (CMV) promoter. 
3.2.7. Mammalian cell lines- HEK293A 
In the present work we choose the HEK293A cells to produce the adenovirus. This cell line is a subclone 
of the HEK cell line that is a permanent line established from primary embryonal human kidney and 
exhibits a relatively flat morphology, that enable an easier visualization on the plaques. 
The genes E1a and E1b are expressed in these cells and participate in transactivation of some viral 
promoters, allowing very high levels of protein production. The protein E1 also complements the E1- 
deletion in recombinant adenoviral vectors, allowing viral replication.   
3.2.8. Transfection 
The cells were seeded in 6-well plates 24h prior to transfection. The transfection mix was prepared 
according to the manufacturer's protocol. We diluted 2 µg of DNA into 500 µl jetPRIME buffer 
(Polyplus Transfection, USA), was added 5 µl of jetPRIME (Polyplus Transfection, USA) and the mix 
was incubated for 30 minutes. 
After the cells reached 60% confluence we added the transfection mix into the plates and we waited for 
9 days.  After that time, we collected the medium and we reinfected new cells with the aim to amplify 
the adenovirus. 
3.2.9. Adenoviral production  
Adenoviral plasmid was purified as described in chapter 3.1.1.1 and 3.1.1.2.  
Adenoviral production was performed by transient transfection. HEK293A cells, cultured with DMEM 
high glucose (Gibco®, Life Technologies, USA) at 50-80% confluence in 25 cm2 polylisin-coated flask, 
were transfected as described in the chapter 3.4. 
Nine days after the transfection, the HEK293A cells released the produced adenovirus particles by 
exocytosis and the supernatants containing these viral particles were collected and centrifuged to clean 
debris. The adenovirus production was evaluated by the transduction.  
3.2.10. Mini scale production and purification of FUT8  
To express a greater amount of protein than the one expressed by the tests mentioned before, a mini 
scale production was performed. 
The cells were seeded in 170 cm3 roller bottles, incubated at 37ᵒC, 5% CO2 until reaching a confluence 
Figure 10- Diagram representing the settings used for pcr amplification with Promega GoTaq DNA Polymerase. 
Initial denaturation (2 minutes at 95ᵒC), followed by 32 cycles of denaturation (20 s at 95ᵒC), primer annealing (20 s at 58ᵒC) 
and extension (variable time). 
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of 50-80%. Then, 160 mL of adenovirus containing supernatant was added to each roller bottle and after 
approximately 48 hours the supernatant was collected and centrifuged at low speed. 
Afterward centrifugation, 200 μl of the supernatant was aliquoted and stored at -80°C, given the name 
"Total" at this aliquot. The pellet was resuspended in 50 mL lysis buffer and vortexed and sonicated in 
4 cycles of 20 seconds, always keeping the samples on ice. 
Then, the lysate was centrifuged at 100,000 g for 1 hour. Next, a 200 μl sample of the supernatant which 
was given the name "Sup" was collected and again aliquoted and stored at -80°C. The remaining 
supernatant was diluted in 100 mL of the wash buffer and maintained on ice. The pellet was resuspended 
in lysis buffer and was aliquoted and stored at -80°C, given the name "pellet". 
The Hight Density Nickel column (Agarose Bead Technologies (ABT), USA) was equilibrated by 
washing with the wash buffer and the supernatant was added to the column. The flow thought was 
collected and aliquoted as the other aliquots mentioned before.  
Th elution was done with the addition of 2 mL of elusion buffer and several samples were collected and 
aliquots at -80. 
3.3. Analytical test- HEK 293A cell line 
3.3.1. Western Blot  
To separate proteins based upon their molecular size, we performed 12% polyacrylamide gels. Gels 
were poured into pre-made gel chambers, and well-forming combs were immediately added, and the gel 
was left to polymerize. After polymerization, combs were removed, and the wells were filled with 
running. The samples were prepared for running on polyacrylamide gels by adding an equal amount 
(500 µl) of loading buffer 3x. Once loading buffer had been added, the samples were heated to 95°C for 
5 minutes, loaded into the polyacrylamide gels along with a molecular weight marker for reference at 
30mA for 30-40 minutes. Following separation of proteins by SDS-PAGE, proteins were transferred 
into nitrocellulose membrane (GE Healthcare Life Science, USA) using the following method. Transfer 
cassettes contained the following layers: a sponge, Whatman 3MM blotting paper, nitrocellulose 
membrane, SDS-PAGE gel, Whatman blotting paper and a sponge (all equipment was pre-immersed in 
transfer buffer containing 20% v/v methanol, 0.19M glycine and 0.05M Tris). The transfer cassette was 
then placed in a transfer tank filled with transfer buffer for 1 hour at 250mA. Following the transfer, 
nitrocellulose membranes were washed for 5 times each time and the Nitrocellulose membranes were 
kept in 2% egg albumin solution in PSB Tween for 1 hour in order to block non-specific binding sites.  
Following blocking, primary antibodies were diluted in PBS Tween 1x solution and incubated with the 
nitrocellulose membrane overnight at 4°C on a rocking table. 
Following incubation with primary antibodies, nitrocellulose membranes were washed in PBS Tween 5 
times for 5 minutes each time. Nitrocellulose membranes were then incubated with secondary antibodies 
in 5% skimmed dried milk (Nestlé, Switzerland) in PBS Tween for 1 hour at room temperature. 
Following incubation, nitrocellulose membranes were again washed in PBS Tween 3 times for 5 minutes 
each time. Proteins were then visualized by incubating nitrocellulose membranes in enhanced 
chemiluminescence (ECL) reagent for 1 minute and exposed to a ChemiDoc Imagers (BIO-RAD) for 
the required amount of time. 
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The antibodies used for Western blot are listed in table 3. 
Table 3- List of antibodies used in Western Blot assay. 
                             Primary Antibody 
 Host Specificity Dilution Origin 
Monoclonal anti-
FUT8 
Mouse Human FUT8 1:1000 
Santa Cruz 
Biotechnology 
Policlonal anti-
GAPDH 
Goat Human 1:2500 Sicgene 
                            Secondary Antibody 
Anti-goat HRP 
conjugated 
Donkey Goat IgG 1:5000 Bio-Rad 
Anti-mouse HRP 
conjugated 
Donkey Mouse IgG 1:5000 Bio-Rad 
 
Mammalian cell lines- HT29 cell line 
The HT29 CRC cell line (ATCC®HTB-38TM) derived from an adenocarcinoma of colon from a 44-
year-old Caucasian female, was used and transduced with adenoviral vector pAd/CMV/V5-DEST™ 
containing the cDNA of the gene that encodes for human FUT8. Similarly, the wild type cell line was 
transduced with an adenoviral empty vector (MOCK) to mimic some effects that the transduction could 
bring to the cells.  
3.4. Cell culture 
HEK293A (figure 13A) and CRC (figure 13B) cell lines were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco®, Life Technologies, USA) supplemented with 10% (v/v) FBS (Gibco®, 
Life Technologies, USA), 1% (v/v) Penicillin/Steptomycin (Gibco®, Life Technologies, USA) and 1% 
(v/v) Glutamine (Gibco®, Life Technologies, USA), in an incubator (Panasonic, Japan) at 37ºC with a 
humidified atmosphere and 5% CO2. The medium was changed every three days. To split the cells at a 
confluence of 80-90%, they were incubated with trypsin ethylenediaminetetraacetic acid (Trypsin-
EDTA) (Gibco®, Life Technologies, USA) for 5-10 minutes, followed by the addition of 3 times the 
volume of trypsin of pre-warmed medium and a centrifugation at 200g, for 5 minutes at RT. 
Routine cell culture manipulations were made on Class II Biosafety Cell Culture Flow Chambers, using 
sterile techniques. Cell stocks were maintained in cryotubes at -80 ºC, resuspended in medium 
supplemented with 10% sterile DMSO. 
Figure 13- Microscopic image of HEK293A (A) and HT29 (B) cell lines acquired at the magnification 10X and 40X, 
respectively, on an inverted microscope. 
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3.4.1. Transduction of colorectal cancer cell line  
The cells (HT29 cell line)  were seeded in a 6-well plate, 10,5x106 cells per well and incubated for 2 
days at 37 ºC in a 5% CO2 atmosphere. After that incubation time, the cells were washed with PBS 1X 
and incubated with the adenoviral supernatants containing the adenovirus in DMEM (Gibco®, Life 
Technologies, USA). In the next day the medium was replaced with a fresh culture medium. 
  
3.5. Biological assays 
3.5.1. Assessment of cell migration capacity 
Cells were grown in monolayer 12-well plates until 100% confluence. Afterwards a scratch was made 
in the monolayer and to remove the debris, the detached cells and smooth the edge of the scratch, cells 
were washed with 1X PBS and then incubated with fresh culture medium at 37ºC with 5% CO2 during 
the experiment. 
Image acquisition of each wound along the time was performed using an inverted microscope (Motic® 
AE31E, China). The first image was acquired instantly after the scratch (T0) followed by periodic 
acquisitions, until 96 h after T0, in the same area of the scratch. 
To calculate the migration area (in µm2) for each wound was subtracted the scratched area at different 
times to the initial scratched area (T0). 
3.5.2. Assessment of cell proliferation capacity 
To evaluate the proliferation capacity of the cells while overexpressing FUT8 we used the CellTraceTM 
carboxyfluorescein succinimidyl ester (CFSE) Cell Proliferation Kit (InvitrogenTM, Life Technologies, 
USA). 
Following trypsin -EDTA detachment, 1×106 cells were resuspended in 2 mL of PBS and 0.2 μM CFSE 
solution was added in a 1:1 proportion, slowly and directly into the tube walls, for a final concentration 
of 0.1 μM. The solution was gently mixed, and the suspension was incubated for 10 minutes at 37ºC in 
the dark. To remove the dye that did not bind to the cells, 10 ml of pre-warmed PBS with 2% FBS was 
added to cells and incubated for 5 minutes at 37ºC, in the dark. 
Following the incubation time, the solution was centrifuged, and the cells were resuspended and cultured 
in pre-warmed DMEM media and incubated for 18 h before any other procedure to allow acetate 
hydrolysis to occur. Cells were collected after 1 (T1), 2 (T2), 3 (T3) and 4 (T4) days.  
3.5.3. Immunofluorescence assay 
Cells were cultured in round coverslips in 24 well plates (Greiner CELLSTAR®, Austria) overnight, 
fixed and permeabilized with 200 µL of wash solution (Fixation/Permeabilization Solution Kit from BD 
Biosciences, USA) for 20 minutes at 4ᵒC. 
After blocking with 1% bovine serum albumin (BSA), cells were stained with different antibodies 
followed by the respective secondary antibodies labelled with different fluorophores. The list of 
antibodies used can be found in Table 1. 
The nucleus were stained with DAPI (Santa Cruz Biotechnology, USA) and the images were acquired 
with (AxioImager D2 - Zeiss) confocal microscope.  
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ble 1- List of antibodies used in Immunofluorescence assay. 
                   Primary Antibody and lectin 
 Host Specificity Dilution Origin 
Monoclonal anti-
FUT8 
mouse Human FUT8 1:100 
Santa Cruz 
Technology 
Biotinylated 
Aleuria Aurantia 
Lectin (AAL) 
 
(α -1,6) linked 
fucose residue 
 
1:100 
VECTOR 
Laboratories 
                    Secondary Antibody 
Anti-mouse FITC Goat Mouse IgG 1:100 Southern Biotech 
Streptavidin 
FITC 
 Biotin 1:100 BD Pharmingen 
 
3.6. Analytical tests 
3.6.1. Real-Time Quantitative Polymerase Chain Reaction Protocol 
3.6.1.1. Gene Expression Analysis- HT29 cell line 
To evaluate the genetic expression of FUT8 and TGF-beta genes, total RNA was extracted and then 
converted  to cDNA by RT-PCR. RNA extraction was performed using the GenElute Mammalian Total 
RNA Miniprep Kit (Sigma Aldrich, USA). 
The lysis buffer was first prepared by the addiction of β-mercaptoethanol (Sigma, USA) to the 
commercial lysis solution in a 1:100 proportion. 
We added 250 µL of the lysis buffer and cells were lysed by throughout pipetting. To remove cellular 
debris and shears DNA the lysed cells were filtered in filtration column by centrifugation at 12000 g for 
2 minutes at 4ᵒC. The filtration column was discarded and 250 µL of 70% ethanol were added to the 
filtered lysate, followed of a mix by vortex. This mixture was placed to the biding column and 
centrifuged at maximum. 
The DNAse I solution was prepared by mixing DNAse I with digestion buffer in a 1:8 proportion and 
80 μL of this solution were added to each column. After incubation for 15 minutes at RT and the columns 
were washed 250 µL of Wash Solution I and centrifuge. 
 The flow-through liquid was discarded, and the biding column was washed by the addiction of 500 µL 
of Wash Solution I and centrifugation. 
The columns were washed twice with 500µL of Wash Solution II.  To remove any residual ethanol the 
empty biding column was centrifuged for 2 minutes at maximum speed (12 000 g) at 4ᵒC. 
To elute the RNA, 50 µL of Elute Buffer was added to the biding column, already in a fresh 2 mL 
collection tube and centrifuged at maximum speed. 
The isolated and purified RNA was converted into cDNA. The conversion of the RNA was performed 
using the High-Capacity cDNA transcription Kit (Applied Biosystems) based on the principle that 
random primers will bind to the RNA, allowing the reverse transcriptase enzyme to perform the 
transcription. To prepare the master mix was added to a 1,5 mL Eppendorf the following reagents: 10 
µL of the buffer, 10 µL of the primers, 4 µL of the dNTPs, 5 µL of the reverse transcriptase enzyme and 
21 µL of RNase free H2O (from Nzytech Kit, Nzytech, Portugal), making the total volume of 50 µL per 
sample.  
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In a PCR tube (VWR, USA) we added 50 µL of the master mix and 50 µL of the purified RNA. The 
conversion was achieved using the program described in the figure 14 on a Programmable Thermal 
Controller PTC-100TM (MJ Research, USA). The cDNA was stored at -20ᵒC. 
 
 
 
 
 
For the qRT-PCR analysis, we used the TaqMan Chemistry and the Rotor-Gene 6000 Series (Corbett 
Research, USA) with the conditions described in Table 2. To perform the reaction, we added 5 µL of 
TaqMan Fast Universal PCR Master Mix 2X, 3 µL of cDNA and 2 µL of diluted probe 1:4 (Applied 
Biosystems). All the experiments were conducted in duplicate and as endogenous controls housekeeping 
genes we used β-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).   
The Rotor- Gene 6000 series software (version 1.7) was used to determine the CT values and the gene 
expression was assessed by the CT method. The relative quantification of mRNA was achieved by the 
normalization of the average of the gene expression of the gene in study against the average of the 
expression of the endogenous genes using the adapted equation 2-ΔCT*1000. 
 
3.6.2. Flow cytometry 
The HT29 CRC cells were detached with TE from the culture flasks and washed with 1X PBS by 
centrifugation at 200xg, for 5 minutes. The supernatant was discarded, and the resultant pellet was 
resuspended in 1 mL of medium and the cells were counted in a 1:10 dilution in a Newbauer chamber 
(Paul Marienfeld, Germany). 3x105 cells per condition were collected in a centrifuge tube and washed 
again. The desired concentration of cells was then washed with 500 μl of PBS 1X and centrifuged at 
1500xg for 2 minutes. The supernatant was discarded, and the preceding step was repeated but with 990 
μl of 1X PBS. The pellets were resuspended in the desired volume of 1X PBS to be divided as 100 μL 
per condition. The primary antibodies were added, and the samples were incubated at 4ºC for 30 
minutes. Another wash step was performed with 500 μl of 1X PBS and centrifuged at 1500xg for 2 
minutes. The supernatant was discarded, and the pellets were resuspended in 100 μL of 1X PBS. The 
secondary antibody was added according to the primary antibody used and the samples were incubated 
at room temperature for 15 minutes in the dark. At the end of this step the cells were again washed with 
500 μl of 1X PBS by centrifugation at 1500xg for 2 minutes. The supernatant was discarded, and the 
pellets were resuspended in 1 ml of 1X PBS to by analyzed by Flow Cytometry. If required, the cells 
were fixed in 4% Paraformaldehyde (PFA) to be analyzed later. 
At least 1x104 events were acquired in the Attune Cytometric Software (version 2.1) and all data was 
analyzed in FlowJo (version10). Upon the flow cytometry acquisition, the strategy adopted to gate cell 
population was as described on figure 15. 
 
Figure 14- Schematic representation of the program the thermal cycler conditions- cDNA synthesis. 
Table 2- RT-PCR reaction conditions. 
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Table 4- List of antibodies used in Flow Cytometry assay. 
 
 
 
 
  
                   Primary Antibodies and lectins 
 Host Specificity Dilution Origin 
Monoclonal anti-
FUT8 
mouse Human FUT8 1:100 
SIGMA-
ALDRICH 
Biotinylated 
Aleuria Aurantia 
Lectin (AAL) 
 
(α -1,6) linked 
fucose residue 
 
1:100 
VECTOR 
Laboratories 
                    Secondary Antibody 
Anti-rabbit FITC Goat Rabbit IgG 1:100 
SIGMA-
ALDRICH 
Streptavidin 
FITC 
 Biotin 1:100 BD Pharmingen 
Figure 15- Gating strategy for flow cytometry acquisitions. The schematic representation characterizes the gating steps 
upon flow cytometry data acquisition. After cell suspension aspiration, the density plot graph FSC-A vs SSC-A on the left is 
generated and then a gate is drawn to cover the cell population. The gate is used to create a histogram graph of fluorescence 
channel vs count (normalized to mode) where the positive cells peak is counted from the end of the unstained peak. 
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4. Results and Discussion  
4.1. General introduction  
Altered glycosylation is a universal feature of cancer cells, and certain glycans are well-known markers 
of tumor progression. Glycans are involved in fundamental molecular and cell biology processes 
occurring in cancer, such as tumor cell dissociation and invasion, cell–matrix interactions, immune 
modulation, tumor angiogenesis, and metastasis formation. 
In the present work, the aim was the development of a molecular tool to assess the expression of 
fucosyltransferase 8 (FUT8). In spite of the numerous reports in which an increase of the expression of 
the protein in several types of cancers is identified, its role is still elusive48,51,52,64. 
In a first phase, the main goal was to develop a adenoviral system to express the FUT8. Subsequently 
we validated the overexpression of FUT8 in colorectal cancer cell lines and evaluated the phenotype, 
proliferation, migration, as well as the expression of growth. 
 
4.2. Molecular Cloning of FUT8  
As a first reaction of the Gateway Technology we had the BP reaction, which its resultant product is an 
entry vector containing the coding sequence for the FUT8 protein. 
After the entry vector was obtained, the plasmid was transformed into HB101 cells with the aim to have 
a working plasmid bank with a subsequent amplification of the produced DNA by PCR. 
The evaluation of transformation efficiency and DNA integrity were assessed by DNA electrophoresis 
gel, using 0,8% (w/v) agarose gels, as previously describe in chapter 3.2.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The figure 17 shows well-defined bands in almost all the selected colonies, which indicates that the 
transformation was successful. 
We chose one colony of transformed bacteria and the colony was grown in 5 mL of LB medium. The 
purification of the plasmid was performed from these bacteria with Plasmid Mini Kit I (Omega, USA) 
following the manufacturer's instructions. 
Also, an enzymatic restriction assay was performed using specific restriction enzyme - NehI - in order 
to confirm the sequence and linearize the plasmid. The resulting fragments were analyzed by DNA gel 
electrophoresis and are shown in Figure 18. 
Table 5: FUT8 codifying gene sequence flanked with attB sequences in puc57 vector synthesized by 
GeneCust (Luxemburg). 
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After the linearization of the vector, was performed the second major reaction of the Gateway 
Technology, the LR reaction. 
This reaction was catalyzed by LR Clonase™ enzyme mix and facilitates recombination of an attL 
substrate (entry clone) with an attR substrate (destination vector) to create an attB-containing expression 
clone. In the particular case of this study, the destination vector that was chosen was an adenoviral 
vector, pAd/CMV/V5-DEST. 
The expression vector was transformed into HB101 cells, again with the aim to have a working plasmid 
bank with a subsequent amplification of the produced DNA by PCR. 
The assessment of transformation efficiency and DNA integrity were evaluated by DNA electrophoresis 
gel. Afterward analyzing the PCR products, one colony was incubated, isolated and purified. An 
enzymatic restriction assay was also performed using a specific restriction enzyme - PacI - to check the 
sequence and linearize the plasmid (figure 19A). The overall plasmid purity, assessed by the 
Abs260nm/Abs280nm is high, as well as the plasmid concentration (figure 19B).  
 
 
 
 
 
 
 
 
 
 
 
The DNA fragments obtained after the gel electrophoresis correspond to the predicted weights 
confirming the high purity and composition of the plasmid. Faced with such results, the final plasmid 
was transfected as described previously in Chapter 3.4.1. HEK293A cells were transfected for producing 
of the replication-incompetent adenovirus. 
Figure 17- Electrophoresis gel of the PCR product of Entry vector using the M13 Forward and M13 Reverse primers. 
Lanes of Entry vector PCR: 1.-17. Picked colonies from the previously inoculated agar plates. 
Figure 18- Electrophoresis gel of the enzymatic digested products of entry purified plasmid. The plasmid was digested 
with NehI restriction enzyme. 
Figure 19- Electrophoresis gel of the enzymatic digested products of the purified plasmid. The plasmid was 
digested with PacI restriction enzyme (A). Purity and concentration of the plasmid (B). 
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4.3. Adenovirus production  
The human HEK293A cell line is a subclone of the HEK293 cell line and contains a stably integrated 
copy of the E1 gene that supplies the E1 proteins (E1a and E1b) required for the expression of adenoviral 
late genes, and thus viral replication.  
This cell line as shown in the figure 20, present a flat morphology that facilities the initial production 
and amplification of the replication-incompetent adenovirus.  
As described before in the chapter 3.4.1, the HEK293A cells were transfected with PacI- digested 
adenoviral plasmid and the figure 20 shows a significant difference relative to the morphology of 
HEK293A cells before and after the infection. In the figure 20 it is represented the cells that were not 
infected with the adenoviral plasmid (upper) and the HEK293A cells infected (lower) over the time. In 
comparation with the non-infected cells, in an early stage(12h), cells producing adenovirus first appear 
as patches of rounding, dying cells. As the infection proceeds, cells containing viral particles lyse, infect 
neighboring cells and a plaque begins to form, being clearly visible over the time. Through this 
evaluation, the results suggest that the cells were producing the adenovirus. 
 
4.4. Validation of FUT8 overexpression using adenoviral system in HEK293A cell line 
It was extremely important to validate the developed molecular system of overexpression of FUT8 in 
order to ensure consistent results throughout future biological experiments and to check if the Gateway 
Technology was a good system for transferring DNA segments between vectors.  
A western blot was performed with an SDS-PAGE electrophoresis (denaturing conditions), to analyze 
the overexpression of FUT8 protein in the cellular extracts. After electrophoresis, the gel was transferred 
to a nitrocellulose membrane (GE Healthcare Life Science, USA) and incubated with anti-FUT8 
(1:1000, Santa Cruz Technology, USA) and anti-mouse alkaline phosphatase conjugated secondary 
antibody (1:5000, Bio-Rad, USA).  The figure 21 shows that the FUT8 recombinant protein is in fact 
being produced in transduced HEK293A cell extracts (clone 1 and 13). Proving that the FUT8 
overexpression-encoding plasmid was correctly constructed. As a negative control, was used HEK293A 
cells that were not transduced with the adenovirus. 
Figure 20- Microscopic image of HEK293A cell line wild type (upper) and infected with the adenoviral plasmid containing 
the encoding sequence of FUT8. The images were acquired at the magnification 10X on an inverted microscope. 
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4.5. FUT8 purification from transduced HEK293A cell extracts  
Following the previous results, we thought that would be challenging to try to purify the enzyme. To 
perform the purification of the recombinant FUT8 protein, cell extracts from transduced HEK293A cells 
and from non-transduced cells (as a negative control) were used. As the recombinant FUT8 protein has 
a C-terminal Histidine tag, a metal ion affinity strategy was used in order to ease the purification process. 
After the purification, as described in the chapter 3.4.3 , using the same approach as before, all samples 
were analyzed by Western Blot (Figure 22), using anti-FUT8 primary antibody (1:1000, Santa Cruz 
Technology, USA) with anti-mouse alkaline phosphatase conjugated secondary antibody (1:5000, Bio-
Rad, USA).The figure 21 shows that was possible to detect a faint band that appears and correspond to 
the predicted size of the recombinant FUT8. 
 
4.6. Validation of FUT8 overexpression using adenoviral system in HT29 cell line 
Although the results obtained during the FUT8 overexpression test in the HEK293A cell line were 
positive, it was again necessary to validate the overexpression of the protein in the HT29 cell line, in 
which future experiments will be conducted, in order to use in a correct and reliable way the built-in 
overexpression system. 
Figure 21- Representative FUT8 identification by Western blot in HEK293A control cells (non-transduced) and cells 
transduced with FUT8 encoding adenovirus. Anti-FUT8 (1:1000, Santa Cruz Biotechnology, USA) and anti-mouse alkaline 
phosphatase conjugated secondary antibody (1:5000, Bio-Rad, USA). Protein extract of HEK293A FUT8 cells were collected 
2 days after transduction. 
Figure 22- Representative FUT8 identification by Western after the purification process. Anti-FUT8 (1:1000, Santa Cruz 
Biotechnology, USA) and anti-mouse alkaline phosphatase conjugated secondary antibody (1:5000, Bio-Rad, USA). Lanes: 
Total. Supernatant containing the adenovirus before the ultra-centrifugation; Pellet. Pellet after the ultra-centrifugation; Sup. 
Supernatant after the ultra-centrifugation. Elu1. 1st elution; Elu2. 2nd elution; Elu3. 3rd elution; Elu4. 4th elution; Elu5. 5th 
elution; Elu6. 6th elution. 
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It is necessary to answer practical and experimental questions in this first phase, so that future results, 
namely the study of the implication of the overexpression of FUT8 in the process of carcinogenesis are 
reliable. 
The results obtained with the HEK293A cell line cannot be transposed to other cell lines, because 
although the overexpression system is the same, the adenovirus transduction process may present 
differences between cell lines. 
The most conditioning factor in the impossibility of transposing results between different cell lines is 
the different expression of the Coxsackie and adenovirus receptors (CAR) by the cells. 
The adenoviruses bind to these receptors (CAR) and only then, they can be internalized and transported 
to the nucleus. 
Thus, it was essential to evaluate the overexpression of FUT8 in the HT29 cell line. 
Two days after transduction, cells were harvested and subjected to different assays in order to evaluate 
FUT8 mRNA expression and protein expression. 
Gene expression was achieved using the Reverse transcription polymerase chain reaction (RT-PCR) 
technique. 
As shown in figure 23 (A), cells transduced with adenoviruses which do not contain the FUT8 coding 
sequence show a relatively low FUT8 mRNA expression relative to cells transduced with the adenovirus 
which contains the FUT8 coding sequence in its plasmid. 
 
To evaluate the expression of FUT8 in the two types of cell lines mentioned above, flow cytometry and 
fluorescence microscopy assays were performed. 
Figure 23 (B), referring to the flow cytometry assay, shows an overexpression of FUT8 in relation to 
cells transduced with adenoviruses with the empty vector (88.8% of expression). 
 
 
 
 
 
 
 
Figure 23- FUT8 expression assessment by RT-PCR (A) and FUT8 assessment by flow cytometry in HT29 MOCK and 
HT29 FUT8 cell lines (B). In the graph (A) is shown the relative mRNA levels of the FUT8 gene. The yy axis represents the 
relative mRNA levels and the xx axis the cell line in study. (B) HT29 CRC cells were staining using FUT8 anti-rabbit first 
antibody (SIGMA ALDRICH, USA) and anti-rabbit IgG FITC (SIGMA ALDRICH, USA). Non-stanning cells, HT29 MOCK 
(blue filled pick) and stained cells, HT29 FUT8 (red filled pick). Control stained just with fluorescent secondary antibody 
(yellow filled pick) was also analyzed. 
The results obtained by fluorescence microscopy were in agreement with those obtained by the 
techniques of RT-PCR and flow cytometry. 
Figure 24 clearly shows a very high expression of FUT8 in the HT29 FUT8 cell line in relation to the 
HT29 MOCK.  
In order to make a more rigorous evaluation of the above images we calculated the "corrected total cell 
fluorescence (CTCF)". 
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This measure of fluorescence intensity consists of the difference between the integrated density and the 
product of the area of each cell by the background fluorescence mean. 
 
 
 
The figure 25 is in accordance with the above results showing a HT29 FUT8 CTCF about 50000 times 
higher than that of HT29 MOCK. 
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Figure 24- Immunofluorescence assay. Analyses show that HT29 FUT8 cell line present an overexpression of FUT8 in 
relation to the non-transduced cells, HT29 MOCK. As a control, HT29 were not stained with FUT8 antibody in order to 
check the specificity of the secondary antibody.  
 
Figure 25- Quantification of the total cell fluorescence of FUT8 staining. The HT29 FUT8 cells shows a higher level of the 
correct a total cell fluorescence (CTCF) in relation to the HT29 MOCK. These results confirm that the transduction was 
successful, and the cells were overexpressing the FUT8. 
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4.7. Evaluation of the abundance of core fucosylation  
Lectins are a special class of proteins widely distributed in nature, which selectively recognize and 
reversibly bind to carbohydrates and glycoconjugates through their binding sites.  
Leuria aurantia lectin (AAL) is a commercially available lectin that is known for its high affinity for 
α1,6-fucosylated oligosaccharides65.  
In order to estimate the extent of α1,6-fucosylation (core fucosylation) on glycoproteins on the surface 
of HT29 cells transduced with adenovirus that contained the encoding sequence of FUT8 in their 
plasmid was performed two different assays: flow cytometry and fluorescence microscopy. Figure 26, 
relative to the cytometric assay shows a significant increase in the extension of α1,6-fucosylation (core 
fucosylation) in glycoproteins to the surface of HT29 FUT8 cells. 
Such results suggest that in addition to transduction having been successfully achieved, FUT8 protein 
is being overexpressed, it is also functional, hence the results show an increase in its end product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It was surprisingly observed that cells that did not have FUT8 modulated expression exhibit a very low 
α1,6-fucosylation (core fucosylation) extension (figure 27 and 28), which according to the literature 
contradicts the reports  that associate an increase in the levels of a(1,6)FT activity in polypoid tumors, 
which are more localized and less invasive than nonpolypoid tumors  and a progressive decrease in 
a(1,6)FT activity as the degree of infiltration in the intestinal wall progressed54. 
Figure 26- FUT8 expression assessment by flow cytometry in HT29 MOCK and HT29 FUT8 cell lines. HT29 CRC 
cells were staining using AAL lectin (VECTOR laboratories, USA) and streptavidin FITC (BD Pharmingen, USA). Non-
stanning cells, HT29 MOCK (yellow filled pick) and stained cells, HT29 FUT8 (green filled pick). Control stained just 
with fluorescent secondary antibody (black filled pick) was also analyzed. 
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Figure 27- Immunofluorescence assay. Analyses show that HT29 FUT8 cell line presents a higher extention of α1,6-
fucosylation (core fucosylation) on glycoproteins on the surface in relation to the non-transduced cells, HT29 MOCK. As a 
control, HT29 were not stained with AAL lectin in order to check the specificity of streptavidin FITC. 
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Figure 28- Quantification of the total cell fluorescence of AAL lectin staining. The HT29 FUT8 cells shows a higher level 
of the correct a total cell fluorescence (CTCF) in relation to the HT29 MOCK. These results confirm that the transduction was 
successful, the cells were overexpressing the FUT8 and the protein is in the active form. 
4.8. Cell morphology of HT29 cell line overexpressing FUT8 
The morphology of HT29 cell lines was evaluated over time with the periodic acquisition of images 
through an inverted microscope (figure 29). The evaluation of the morphology revealed no significant 
difference of the HT29 FUT8 cell line in relation to the HT29 MOCK cell line as would be expected, 
because of the aggressive character overexpression of FUT8 has been shown in many types of cancers. 
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4.9. Impact of overexpression of FUT8 on CRC cells phenotype 
4.9.1. Proliferation properties of CRC cells overexpressing FUT8 
One of the most striking features of the carcinogenesis process is the chronic proliferation and 
consequently the evasion of growth suppressors. 
Uncontrolled proliferation of cancer cells can be triggered and sustained by different mechanisms such 
as autocrine, endocrine and paracrine signaling. This ability can also be a result of downstream 
alterations of intracellular circuits resulting in constitutive receptor activation.  Thus, it becomes quite 
interesting and challenging to study if the overexpression of FUT8 has implications on the mechanism 
of cancer cell proliferation. For this, an assay was conducted in which the proliferation of the HT29 cells 
was evaluated using the Carboxyfluorescein succinimidyl ester dye.  
CFSE is a fluorescent cell staining dye. CFSE is a cell permeable and covalently couples, via its 
succinimidyl group, to primary amines located inside the cells. Due to this covalent coupling reaction 
fluorescent CFSE can be retained within the cells for extremely long periods. The linkage of the dye to 
the intracellular molecules is stable, not being transferred to adjacent cells. The fluorescent dye is diluted 
as the cells divide, being a very good tool to follow multiple generations and evaluate the proliferation 
of the cells. 
The results obtained demonstrate that overexpression of FUT8 may be implicated in the process of cell 
proliferation. As can be seen in figure 30 (A and B) and 31, the HT29 FUT8 cell line has a higher 
proliferation index than the HT29 MOCK cell line over time, which is in accordance with the numerous 
associations that have been made, linking the overexpression of FUT8 with the aggressiveness and 
malignant properties of different types of cancers. 
These results also support the hypothesis that FUT8 is necessary in maintaining the aggressiveness and 
malignancy of tumor cells and it is in agreement with the model that propose that during the process of 
epithelial–mesenchymal transition (EMT), cancer cells lose the expression of E-cadherin, leading to the 
nuclear accumulation of β-catenin. The nuclear β-catenin then cooperates with lymphoid enhancer-
binding factor-1 (LEF-1) to activate FUT8 expression. The global alteration of core fucosylation on cell 
surface molecules following FUT8 up-regulation changes the response of cancer cells to their 
microenvironment, including extracellular matrix and growth factors, which in turn promote the 
progression of cancer cells via activating the malignancy-associated genes66. 
Figure 29- Morphology evaluation of both HT29 FUT8 and HT29 MOCK cell lines with 10x magnification. 
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The expression of growth factors was evaluated by RT-qPCR and quantified by the method presented 
by Livak and Schmittgen67. The method defines the variation in the expression of a certain gene in 
relation to a control (untreated sample). The CT designates the cycle number at which the amount of 
amplified target reaches a fixed threshold, ΔCT stands for the difference between the CT of the target 
gene and that of the endogenous controls. The normalization step provides a way to correct results for 
different amounts of input RNA. 
An increase in the expression of TGF-beta in the HT29 FUT8 cell line was also observed (figure 32), 
which is again in agreement with the mention above hypothesis, since it hypnotize that the E-cadherin/β-
catenin signaling pathway plays a key role in regulating EMT via cross-talk with the TGF-β1 signaling 
pathway. Loss of E-cadherin expression caused by the TGF-β1 signaling pathway leads to the 
Figure 31- Proliferation index of both HT29 FUT8 and HT29 MOCK cell lines for 5 days was analyzed by flow 
cytometry. After staining 24, 48, 72, 96 and 120hours cells were collected. 18 hours after staining was assumed as initial 
time, because it is the time necessary for the hydrolysis of the acetate group by intracellular esterases allowing the exposure 
the succinimidyl group of the fluorescent CFSE. The data shows a higher proliferation index of HT29 FUT8 relative to HT29 
MOCK. 
  
Figure 30- Proliferation properties of CRC cells overexpressing FUT8 by flow cytometry. CFSE-stained HT29 cell 
line subjected to the stained during 24 H (blue), 48 H (orange), 72 H (light green) and 96 H (dark green), unstimulated 
CFSE-stained PBMCs (brown). 
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translocation of β-catenin from plasma membrane to the nucleus, where it complexes with LEF-1 to 
promote EMT66. 
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4.9.2. Migration properties of CRC cells overexpressing FUT8 
Invasion and migration of cancer cells into surrounding tissue and the vasculature is an initial step in 
adenocarcinomas, the most common human cancers. In metastasis, cancer cells break away from the 
original (primary) tumor, travel through the blood or lymph system, and form a new tumor in other 
organs or tissues of the body68. Metastasis is the most frequent cause of death for patients with cancer 
and its molecular mechanisms are poorly understood because of its complexity.   
From the interesting results obtained previously, suggesting that the overexpression of FUT8 would 
have implications in the cell proliferation, we thought it would be interesting to see if modulating the 
expression of this such important protein would also have an implication in the migration of cancer cells. 
Our collected data demonstrated that the overexpression of FUT8 increase migration capacity of CRC 
cancer cells (figure 33 and 34). 
The RT-PCR assay showed an increase of expression of the transforming growth factor (TGF-β), 
another growth factor that is been linked to the migration and invasion capacity of cancer cells.  
Studies have demonstrated that FUT8 is upregulated during TGF-β-induced EMT and upregulated 
FUT8 remodeled the core-fucosylated N-glycans on cell-surface targets such as TGF-β RI and RII 
complexes to enhance ligand binding and promote downstream signal activity. Together, these events 
facilitate the transformation of the epithelial phenotypes toward mesenchymal features, with increased 
migratory and invasive capabilities in cancer cells70. 
These results are in line with experiments performed in different cancer cell lines, that showed that the 
upregulation of FUT8 has implications in the migration capacity of breast cancer cells70, prostate cancer 
cells (PC3 and LNCaP) and may be associated with aggressive PCa71. Reports also associate that the 
Inhibition of core fucosylation suppresses human liver cancer HepG2 cell migration as well as tumor 
formation72. 
 
Figure 32- Gene expression of TGF-beta growth factor expressed by HT29 FUT8 cell line was compared to the one 
expressed by HT29 MOCK cell line. Relative mRNA expression) indicates the relative change in mRNA expression levels 
from the FUT8 expression modified cells relative to the unmodified cells.  
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Figure 34-Migration area. Migration area after the scratch (µm2) was quantified at each time point by subtraction of the 
scratched area at the different time points to the scratches area at T0. The results show a higher migration area of HT29 FUT8 
in relation to HT29 MOCK cell line, showing that FUT8 may has implication in the migration capacity of CRC cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33- Effect of FUT8 overexpression on the migration capacity of HT29 cell line. Representative images of wound 
healing assays in both HT29 FUT8 and HT29 MOCK cell lines, at TO (0 h), T1 (24 h), T2 (48 h) and T3 (72 h) after scratch. 
Wound border was represented by yellow dashed lines (0 h) and pink dashed lines (T1, T2 and T3), for both cell lines. 
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5. Final remarks and future perspectives  
CRC begins as a growth called a polyp inside the colon or rectum. It is a major cause of mortality 
throughout the world and it accounts for over 9% of all cancer incidence, being the third most common 
cancer worldwide and the fourth most common cause of death. The survival of this kind of cancer highly 
depends upon the stage of disease at diagnosis, and typically ranges from a 90% 5-year survival rate for 
cancers detected at the localized stage; 70% for regional; to 10% for people diagnosed for distant 
metastatic cancer. So it is urgent to try to find new approaches to detect the cancer in the initial steps, 
not compromising the comfort of the patients73.  
Glycosylation is the process of addition of glycans to glycoproteins and is the major posttranslational 
modification of proteins which play an important role in malignant transformation and metastasis. 
Aberrant glycosylation affects the regulation of cell adhesion, migration and proliferation. Nowadays 
glycosylation is considered a new hallmark of cancer, reflecting cancer specific changes in glycan 
biosynthesis pathways such as altered expression of glycosyltransferases and glycosidases. Modification 
on the process of glycosylation it is linked to tumor initiation, progression and metastasis.  
In view of these facts, the work developed within the scope of this thesis had the objective to understand 
the implications of overexpressing of the FUT8 in CRC cells. For that, we developed a molecular tool 
using the adenoviral expression system to overexpress FUT8, validate the same system in the cell lines 
in study, and evaluate if the modulation of the expression of this enzyme has implications on the 
hallmarks of cancer: proliferation advantages, invasion and metastasis.  
The proliferation and migration assays suggested that the overexpression of the FUT8 in CRC cells 
increase the proliferation rate and increase the migration capacity, respectively. Our data shows also that 
the overexpression of the enzyme change the expression the different growth factors, supporting the 
hypothesis that the increase of expression of FUT8 has significant implications on the process of 
tumorigenesis.  
Having in mind that the results obtained in the present work are quite interesting, as future perspectives 
we would want to continue the study and deeply explore the hypothesis postulated in this work.  
The first hypothesis establishes a model that propose that during the process of epithelial–mesenchymal 
transition (EMT), cancer cells lose the expression of E-cadherin, leading to the nuclear accumulation of 
β-catenin. The nuclear β-catenin then cooperates with lymphoid enhancer-binding factor-1 (LEF-1) to 
activate FUT8 expression. The global alteration of core fucosylation on cell surface molecules following 
FUT8 up-regulation changes the response of cancer cells to their microenvironment, including 
extracellular matrix and growth factors, which in turn promote the progression of cancer cells via 
activating the malignancy-associated genes. We want to use different stages of the CRC cell lines to test 
this hypothesis, evaluate the level of expression of β-catenin and LEF-1 in the cells that are or not 
overexpressing FUT8 and in other hand, use the TGF-β1 to induce the EMT and evaluate the expression 
of FUT8.  
We thought that also would could be interesting to construct a lentiviral-based approach to overexpress 
and knockdown the FUT8 since these systems allow to establish a stable cell line overexpressing or 
inhibiting a certain protein.  
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